Clinical trial Recruiting at 1 site Observational

How screening patterns relate to early-stage lung cancer in newly diagnosed patients

Official title: A Multicenter, Prospective, Observational Study on the Association Between Real-World Lung Cancer Screening Behaviors and Lung Cancer Disease Spectrum

Run by Fudan University · NCT07626177 · Data updated 2026-11-12

This study looks at how different lung cancer screening behaviors relate to catching cancer early in patients who were recently diagnosed.

Quick facts

Study typeObservational
SexAll
Enrollment5390 (estimated)
SponsorFudan University
Academic / other
Drugs / interventionsradiation
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedMay 14, 2026
Main results expectedMay 1, 2027
Study endsJune 1, 2027
Registry record updatedJune 4, 2026
Trial IDNCT07626177 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with histologically confirmed primary lung cancer diagnosed within the past year who can accurately recall or provide prior medical history.

Probably not a fit

Patients with recurrent or metastatic lung cancer or those unable to provide essential clinical data may not benefit from the findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study analyzes real-world data from patients with newly diagnosed primary lung cancer to describe epidemiology and disease spectrum, including age, gender, smoking history, and pathology. It compares screening patterns—overscreening, underscreening, guideline-concordant, and precision screening—to see how they affect the likelihood of detecting cancer in the curative time window (AIS/MIA or pure GGNs) and to estimate related costs and radiation exposure. The goal is to evaluate whether a low-age, low-frequency screening approach could improve early-stage capture. The analysis relies on retrospective or contemporaneous patient information and pathology data captured before or around diagnosis.

Why it matters

Potential benefit: If successful, the findings could inform screening policy to improve early detection while potentially reducing unnecessary radiation exposure.

How similar studies have gone: Previous observational work has shown associations between screening patterns and cancer detection, but this study adds real-world context focused on early-stage capture and cost implications.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Histologically confirmed primary lung cancer within the past year (surgical or biopsy pathology).
* Patients capable of clearly recalling or providing medical and physical examination history prior to diagnosis.

Exclusion Criteria:

* Recurrent lung cancer or metastatic lung tumors.
* Severe lack of critical clinical data (e.g., inability to provide pathological type or stage).
* Patients with cognitive impairment or severe mental illness who cannot cooperate with the questionnaire.

Where it's running

  • Fudan University Cancer Center
    Shanghai, Shanghai Municipality, China
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.